Beijing Mabworks Biotech Co., Ltd.
17
9
13
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
29%
5 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Role: lead
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
Role: lead
A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Role: lead
A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy
Role: lead
A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Role: lead
A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy
Role: lead
Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis
Role: lead
A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas
Role: lead
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Role: lead
Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
Role: lead
A Clinical Study of MIL95 in Advanced Malignancies.
Role: lead
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Role: lead
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Role: lead
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Role: lead
A Clinical Study of MIL93 in Solid Tumors.
Role: lead
Treatment of Advanced and Metastatic Solid Tumors With MIL97
Role: lead
mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer
Role: lead
All 17 trials loaded